Clincosm LogoSign in Get a demo

cancer of unknown primary site

Showing 1 - 10 of 10
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma Trial in Copenhagen, Århus

Recruiting
  • Cancer of Unknown Primary Site
  • +2 more
  • Transoral Ultrasound
  • Copenhagen, Denmark
  • +1 more
May 2, 2023

Cancer of Unknown Primary Site Trial in Worldwide (Alectinib, Vismodegib, Ipatasertib)

Active, not recruiting
  • Cancer of Unknown Primary Site
  • Blacktown, New South Wales, Australia
  • +140 more
Jan 6, 2023

Carcinoma of Unknown Primary: A Comparison Across Tissue and

Recruiting
  • Cancer of Unknown Primary Site
    • Bath, United Kingdom
    • +6 more
    Oct 18, 2022

    Cancer of Unknown Primary Site Trial in Houston (Sintilimab)

    Recruiting
    • Cancer of Unknown Primary Site
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 31, 2022

    Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency Trial in Australia (APL-501)

    Completed
    • Solid Tumor
    • +3 more
    • Camperdown, New South Wales, Australia
    • +4 more
    May 5, 2022

    Cancer of Unknown Primary Site Trial in Bendigo, Melbourne, Warrnambool (68Ga-FAPi-46, PET/CT imaging)

    Not yet recruiting
    • Cancer of Unknown Primary Site
    • Bendigo, Victoria, Australia
    • +2 more
    Feb 28, 2022

    Cancer of Unknown Primary Site Trial in Shanghai (tissue-of-origin (ORIGIN-PanCA?R) profiling)

    Completed
    • Cancer of Unknown Primary Site
    • tissue-of-origin (ORIGIN-PanCA○R) profiling
    • Shanghai, China
      Fudan University Cancer Hospital
    Jan 21, 2022

    Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site Trial in Cambridge (FoundationOne CDx and FoundationOne Liquid

    Recruiting
    • Rare Cancers
    • +2 more
    • FoundationOne CDx and FoundationOne Liquid CDx
    • Cambridge, Massachusetts
      TargetCancer Foundation
    Oct 13, 2021

    First-line Treatment Among Cancer of Unknown Primary in China

    Recruiting
    • Cancer of Unknown Primary Site
    • no intervention
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cencer Center
    Jul 6, 2021

    Cancer of Unknown Primary Site Trial in Heidelberg (Nivolumab/Ipilimumab)

    Recruiting
    • Cancer of Unknown Primary Site
    • Nivolumab/Ipilimumab
    • Heidelberg, Germany
      University of Heidelberg
    Apr 14, 2020